Identification

Name
Bromazepam
Accession Number
DB01558
Type
Small Molecule
Groups
Approved, Illicit
Description

One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines.

Structure
Thumb
Synonyms
  • Bromazepamum
  • Lectopam
External IDs
RO 5-3350
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-bromazepam 1.5mg TabletsTablet1.5 mgOralAltimed Pharma Inc.1996-12-312005-05-27Canada
Alti-bromazepam 3mg TabletsTablet3 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-bromazepam 6mg TabletsTablet6 mgOralAltimed Pharma Inc.1996-12-312005-05-27Canada
Bromazepam-1.5 - Tab 1.5mgTablet1.5 mgOralPro Doc Limitee1997-05-202010-07-13Canada
Bromazepam-3 - Tab 3mgTablet3 mgOralPro Doc Limitee1996-12-04Not applicableCanada
Bromazepam-6 - Tab 6mgTablet6 mgOralPro Doc Limitee1996-12-04Not applicableCanada
Gen-bromazepam - Tab 3mgTablet3 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Gen-bromazepam - Tab 6mgTablet6 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Lectopam Tab 1.5mgTablet1.5 mgOralHoffmann La Roche1986-12-312006-07-25Canada
Lectopam Tab 3mgTablet3 mgOralHoffmann La Roche1981-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bromazepam - Tab 1.5mgTablet1.5 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-bromazepam - Tab 3mgTablet3 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-bromazepam - Tab 6mgTablet6 mgOralApotex Corporation1995-12-31Not applicableCanada
International/Other Brands
Calmepam / Creosedin / Durazanil / Lectopam / Lekotam / Lexaurin / Lexilium / Lexomil / Lexotan / Normoc / Ultramidol
Categories
UNII
X015L14V0O
CAS number
1812-30-2
Weight
Average: 316.153
Monoisotopic: 315.000724604
Chemical Formula
C14H10BrN3O
InChI Key
VMIYHDSEFNYJSL-UHFFFAOYSA-N
InChI
InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
IUPAC Name
7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1

Pharmacology

Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

Structured Indications
Pharmacodynamics

Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

Mechanism of action

Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit theta
potentiator
Human
Absorption

Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.

Volume of distribution

1.56 L/kg

Protein binding

70%

Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

Route of elimination

Urine (69%), as metabolites

Half life

10-20 hours

Clearance

0.82 mL/min/kg.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Bromazepam can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bromazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Bromazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Bromazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Bromazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.Approved, Investigational
ArmodafinilThe metabolism of Bromazepam can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Bromazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azaperone.Investigational, Vet Approved
AzelastineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Bromazepam can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Bromazepam can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bromazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bromazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Bupivacaine.Approved, Investigational
BuprenorphineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Bromazepam can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Bromazepam is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Bromazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Bromazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Bromazepam can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Bromazepam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Bromazepam can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bromazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Bromazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Bromazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam.Approved, Illicit
ConivaptanThe serum concentration of Bromazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Bromazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.Approved
CyclosporineThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Bromazepam can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Bromazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Bromazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Bromazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bromazepam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Bromazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Bromazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.Approved, Illicit
DihydroergotamineThe metabolism of Bromazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Bromazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Bromazepam can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Bromazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Bromazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
DronedaroneThe metabolism of Bromazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Bromazepam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Bromazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Bromazepam can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Bromazepam can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Bromazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam.Approved
EthanolBromazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Bromazepam can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Bromazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Bromazepam can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Bromazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bromazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bromazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Bromazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Bromazepam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Bromazepam.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Bromazepam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
IdelalisibThe serum concentration of Bromazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Bromazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Bromazepam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indiplon.Investigational
IsavuconazoniumThe metabolism of Bromazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bromazepam.Approved, Vet Approved
IsoniazidThe metabolism of Bromazepam can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Bromazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bromazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bromazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Bromazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam.Approved
LidocaineThe metabolism of Bromazepam can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lithium.Approved
LobeglitazoneThe metabolism of Bromazepam can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Bromazepam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lormetazepam.Approved
LovastatinThe metabolism of Bromazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.Approved
LuliconazoleThe serum concentration of Bromazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bromazepam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Bromazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Bromazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.Approved
MethadoneBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam.Approved
MethotrimeprazineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methylphenobarbital.Approved
MetyrosineBromazepam may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Bromazepam can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.Approved, Illicit
MidostaurinThe metabolism of Bromazepam can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Bromazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bromazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Investigational
MirtazapineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Bromazepam can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Bromazepam can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Bromazepam can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam.Approved
NefazodoneThe metabolism of Bromazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bromazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bromazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bromazepam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Bromazepam can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Bromazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.Approved, Investigational
OlaparibThe metabolism of Bromazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Bromazepam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Bromazepam is combined with Opium.Approved, Illicit
OrphenadrineBromazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bromazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.Approved
PantoprazoleThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.Approved
ParaldehydeBromazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Bromazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Bromazepam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bromazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Bromazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBromazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromazepam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Bromazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Bromazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Bromazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Bromazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam.Approved, Investigational
RifabutinThe metabolism of Bromazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bromazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bromazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Bromazepam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Romifidine.Vet Approved
RopiniroleBromazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ropivacaine.Approved
RotigotineBromazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Bromazepam.Approved
SaquinavirThe metabolism of Bromazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Bromazepam can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.Approved, Vet Approved
SildenafilThe metabolism of Bromazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Bromazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bromazepam can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Bromazepam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Bromazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Bromazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sultopride.Experimental
SuvorexantBromazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Bromazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Bromazepam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Bromazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam.Approved
Tenofovir disoproxilThe metabolism of Bromazepam can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrodotoxin.Investigational
ThalidomideBromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bromazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Bromazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Bromazepam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Bromazepam is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Bromazepam can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Bromazepam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Veralipride.Experimental
VerapamilThe metabolism of Bromazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Bromazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Bromazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bromazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zolazepam.Vet Approved
ZolpidemBromazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Bromazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Bromazepam can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451]
  2. Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [PubMed:14517708]
  3. van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [PubMed:8846617]
  4. Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [PubMed:2882883]
External Links
Human Metabolome Database
HMDB15511
KEGG Drug
D01245
PubChem Compound
2441
PubChem Substance
46505694
ChemSpider
2347
ChEBI
31302
ChEMBL
CHEMBL277062
Therapeutic Targets Database
DAP001035
PharmGKB
PA10035
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromazepam
ATC Codes
N05BA08 — Bromazepam
AHFS Codes
  • 28:24.08 — Benzodiazepines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusPreventionNausea / Vomiting1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1.5 mg
TabletOral3 mg
TabletOral6 mg
Prices
Unit descriptionCostUnit
Lectopam 6 mg Tablet0.25USD tablet
Lectopam 3 mg Tablet0.17USD tablet
Apo-Bromazepam 6 mg Tablet0.13USD tablet
Gen-Bromazepam 6 mg Tablet0.13USD tablet
Novo-Bromazepam 6 mg Tablet0.13USD tablet
Apo-Bromazepam 3 mg Tablet0.09USD tablet
Gen-Bromazepam 3 mg Tablet0.09USD tablet
Novo-Bromazepam 3 mg Tablet0.09USD tablet
Apo-Bromazepam 1.5 mg Tablet0.07USD tablet
Gen-Bromazepam 1.5 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0399 mg/mLALOGPS
logP2.09ALOGPS
logP2.54ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.24ChemAxon
pKa (Strongest Basic)2.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.35 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity76.99 m3·mol-1ChemAxon
Polarizability28.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.9848
Caco-2 permeable+0.7571
P-glycoprotein substrateSubstrate0.5741
P-glycoprotein inhibitor INon-inhibitor0.7251
P-glycoprotein inhibitor IINon-inhibitor0.924
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.8385
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7117
CYP450 1A2 substrateInhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.8511
CYP450 2C19 inhibitorNon-inhibitor0.5719
CYP450 3A4 inhibitorNon-inhibitor0.7405
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6441
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8704
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9974
hERG inhibition (predictor II)Non-inhibitor0.7977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00n0-9463000000-abe7fdab778f08fe18c4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0049000000-67c4bd48b889caf68ca3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0090000000-8d6819f4db99e73f4dbe
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-002r-6090000000-f5e0ef1096bea72d5c89
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9010000000-19864d6c0a50c513bb18
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-59557fda51a0ea2c63d7
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0379000000-14ceeb34a706f6a12f41
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0009000000-09662342e908d558048e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0029000000-4b93291583996cb3cbda
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05o0-0492000000-035f589c482b481c5152
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053r-1890000000-1997ad0374625359f483
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053r-1960000000-4f105348e7e7804313ce
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053r-1930000000-b0f688a41f88a133b74b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f89-1910000000-c0dd1d47a44a292c87b6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-2900000000-706d4c35cde468a8387d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-6900000000-85795e315602b7e61a6b

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Pyridines and derivatives / Benzenoids / Aryl bromides / Heteroaromatic compounds / Secondary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds
show 5 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl bromide / Aryl halide / Pyridine / Benzenoid / Heteroaromatic compound / Carboxamide group / Ketimine / Lactam
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transmembrane signaling receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRQ
Uniprot ID
Q9UN88
Uniprot Name
Gamma-aminobutyric acid receptor subunit theta
Molecular Weight
72020.875 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on July 31, 2007 07:10 / Updated on November 13, 2017 21:49